Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Look AHEAD: Action for Health in Diabetes
Brief Summary: The Look AHEAD study is a multi-center, randomized clinical trial to examine the long-term effects of a lifestyle intervention designed to achieve and maintain weight loss. The study will investigate the effects of the intervention on heart attacks, stroke and cardiovascular-related death in individuals with type 2 diabetes who are also overweight or obese.


Options:
A: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
B: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Care; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, amlodipine, hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil, amlodipine, hydrochlorothiazide; Assigned to Arm(s): Experimental Care
D: Arm Label: Aerobic Exercise (Ex); Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training, Other: Usual Care | Arm Label: Intensive Reduction of Vascular Risk Factors (IRVR); Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Stretching Exercise | Arm Label: IRVR+Ex; Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care, Behavioral: Stretching Exercise | Intervention Type: DRUG; Name: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine); Assigned to Arm(s): IRVR+Ex, Intensive Reduction of Vascular Risk Factors (IRVR) | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Aerobic Exercise (Ex), IRVR+Ex | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Aerobic Exercise (Ex), Usual Care | Intervention Type: BEHAVIORAL; Name: Stretching Exercise; Assigned to Arm(s): Intensive Reduction of Vascular Risk Factors (IRVR), Usual Care

Answer: A